HER2: Biology, Detection, and Clinical Implications

Overview

Journal Arch Pathol Lab Med

Specialty Pathology

Date 2011 Jan 6

PMID 21204711

Citations 249

Authors

Carolina Gutierrez

Rachel Schiff

Affiliations

Soon will be listed here.

Abstract

Context: HER2 is a membrane tyrosine kinase and oncogene that is overexpressed and gene amplified in about 20% of breast cancers. When activated it provides the cell with potent proliferative and antiapoptosis signals and it is the major driver of tumor development and progression for this subset of breast cancer. When shown to be overexpressed or amplified by appropriate methods, HER2 is a valuable treatment target.

Objectives: To review the basic biology of the HER2 signaling network, to discuss various approved methods for its detection in clinical specimens, and to describe the impressive results of therapies targeting HER2.

Data Sources: Selected literature searchable on PubMed as well as older studies revealed by the literature review were reviewed.

Conclusion: HER2 is an important member of a complex signaling network and when gene amplified, it results in an aggressive subtype of breast cancer. Patients with tumors found to overexpress HER2 protein or to be amplified for the gene are candidates for therapy that significantly reduces mortality.

Citing Articles

Assessment of the Efficacy and Pulmonary Toxicity of Trastuzumab Deruxtecan in HER2-Positive and HER2-Low Metastatic Breast Cancer in a Tertiary Center in the United Arab Emirates.

Hourani M, Bdair R, Dawoud E, Trad D, Giridharan S, Al Qawasmeh K Cureus. 2025; 17(2):e78471.

PMID: 40062154 PMC: 11885178. DOI: 10.7759/cureus.78471.

Development of a bispecific antibody-drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors.

Luo M, Wang X, Yu G, Ji J, Li L, Song F Exp Hematol Oncol. 2025; 14(1):33.

PMID: 40057807 PMC: 11889805. DOI: 10.1186/s40164-025-00624-9.

assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications.

Nicolo E, Serafini M, Munoz-Arcos L, Pontolillo L, Molteni E, Bayou N J Liq Biopsy. 2025; 2:100117.

PMID: 40028485 PMC: 11863949. DOI: 10.1016/j.jlb.2023.100117.

A Site-Specific MiniAp4-Trastuzumab Conjugate Prevents Brain Metastasis.

Masmudi-Martin M, Oller-Salvia B, Perea M, Teixido M, Valiente M, Giralt E Mol Pharm. 2025; 22(3):1384-1395.

PMID: 39924896 PMC: 11881140. DOI: 10.1021/acs.molpharmaceut.4c01091.

Hormone and HER2-receptor status in breast cancer: determination using sonographically guided core needle biopsy and correlation with excision specimen-a German single institution diagnostic accuracy study.

Pruss M, Cieslik J, Torok J, Dobrowolski J, Neubacher M, Helbig M Arch Gynecol Obstet. 2025; .

PMID: 39912929 DOI: 10.1007/s00404-024-07920-5.

References

Perez E, Suman V, Davidson N, Martino S, Kaufman P, Lingle W . HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006; 24(19):3032-8. DOI: 10.1200/JCO.2005.03.4744. View

Moasser M . The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007; 26(45):6469-87. PMC: 3021475. DOI: 10.1038/sj.onc.1210477. View

Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

Shousha S, Peston D, Amo-Takyi B, Morgan M, Jasani B . Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology. 2009; 54(2):248-53. DOI: 10.1111/j.1365-2559.2008.03185.x. View

Slamon D, Press M . Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. J Natl Cancer Inst. 2009; 101(9):615-8. DOI: 10.1093/jnci/djp092. View

Sauter G, Lee J, Bartlett J, Slamon D, Press M . Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009; 27(8):1323-33. DOI: 10.1200/JCO.2007.14.8197. View

Marchio C, Lambros M, Gugliotta P, Verdun di Cantogno L, Botta C, Pasini B . Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol. 2009; 219(1):16-24. DOI: 10.1002/path.2574. View

Gustavson M, Bourke-Martin B, Reilly D, Cregger M, Williams C, Mayotte J . Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis. Arch Pathol Lab Med. 2009; 133(9):1413-9. DOI: 10.5858/133.9.1413. View

Allred D, Clark G, Molina R, Tandon A, Schnitt S, Gilchrist K . Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992; 23(9):974-9. DOI: 10.1016/0046-8177(92)90257-4. View

10.

Nahta R, Yuan L, Zhang B, Kobayashi R, Esteva F . Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005; 65(23):11118-28. DOI: 10.1158/0008-5472.CAN-04-3841. View

11.

Weigelt B, Hu Z, He X, Livasy C, Carey L, Ewend M . Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005; 65(20):9155-8. DOI: 10.1158/0008-5472.CAN-05-2553. View

12.

Kallioniemi O, Kallioniemi A, Kurisu W, Thor A, Chen L, Smith H . ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A. 1992; 89(12):5321-5. PMC: 49283. DOI: 10.1073/pnas.89.12.5321. View

13.

Jones K, Buzdar A . Evolving novel anti-HER2 strategies. Lancet Oncol. 2009; 10(12):1179-87. DOI: 10.1016/S1470-2045(09)70315-8. View

14.

Schulze W, Deng L, Mann M . Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol. 2006; 1:2005.0008. PMC: 1681463. DOI: 10.1038/msb4100012. View

15.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

16.

Molina M, Saez R, Ramsey E, Garcia-Barchino M, Rojo F, Evans A . NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res. 2002; 8(2):347-53. View

17.

Blackwell K, Burstein H, Storniolo A, Rugo H, Sledge G, Koehler M . Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010; 28(7):1124-30. DOI: 10.1200/JCO.2008.21.4437. View

18.

Nahta R, Yu D, Hung M, Hortobagyi G, Esteva F . Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006; 3(5):269-80. DOI: 10.1038/ncponc0509. View

19.

Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J . Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007; 99(8):628-38. DOI: 10.1093/jnci/djk134. View

20.

Yarden Y . Biology of HER2 and its importance in breast cancer. Oncology. 2001; 61 Suppl 2:1-13. DOI: 10.1159/000055396. View